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Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) is an uncommon, idiopathic partial epilepsy char-
acterized by clusters of motor seizures occurring in sleep. We describe a mutation of the b2 subunit of the nicotinic
acetylcholine receptor, effecting a V287M substitution within the M2 domain. The mutation, in an evolutionary
conserved region of CHRNB2, is associated with ADNFLE in a Scottish family. Functional receptors with the
V287Mmutation are highly expressed in Xenopus oocytes and characterized by an ∼10-fold increase in acetylcholine
sensitivity. CHRNB2 is a new gene for idiopathic epilepsy, the second acetylcholine receptor subunit implicated in
ADNFLE.
The autosomal dominant nocturnal frontal lobe epilepsy
(ADNFLE) phenotype (MIM 600513) is clinically dis-
tinctive and is relatively homogeneous between families,
although seizure severity and specific frontal lobe seizure
manifestations vary within families (Scheffer et al. 1995).
Site-specific mutations within the a4 subunit of the nic-
otinic acetylcholine receptor (nAChR) are associated
with ADNFLE (Steinlein et al. 1995, 1997, 2000; Hirose
et al. 1999; Saenz et al. 1999; Phillips et al. 2000) and
affect amino acids that face into the pore of the ion
channel, with demonstrated functional effects (Weiland
et al. 1996; Kuryatov et al. 1997; Steinlein et al. 1997;
Bertrand et al. 1998). The main functional nAChR in
the brain is a pentamer comprised of a4 and b2 subunits,
and the second transmembrane (M2) domains of these
subunits interact to form the wall of the ion channel.
Thus, the gene for the b2 subunit (CHRNB2), and its
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M2 domain in particular, is an obvious candidate for
mutation in families and sporadic cases in which there
is no mutation in CHRNA4. De Fusco et al. (2000)
report such a mutation, at the same valine site at which
we now report a different amino acid substitution.
The proband (V-1; fig. 1), a white girl of normal in-
tellect, presented at age 11 years with nocturnal seizures.
She would awaken from sleep with a sensation of
breathing difficulty. After a few seconds, she would ap-
pear to hold her breath and grunt. Sometimes she would
recover quickly and cry or scream. On other occasions,
tonic extension of her left arm occurred with truncal
flexion. Seizures would last up to a few minutes, and
stereotyped attacks recurred at around 15-min intervals
throughout the night. She had clear recollections of these
events. Seizures also occurred during a daytime sleep.
Video EEG telemetry showed only muscle artifact during
the seizure. Although her seizures were initially well con-
trolled by carbamazepine, relapse occurred, and further
control was difficult. Currently, she is seizure free, be-
cause of a combination of phenytoin and topiramate.
There are nine other affected family members span-
ning four generations. Symptoms in the majority either
have been so mild that medical attention has not been
sought or have been easily controlled by carbamazepine.
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Figure 1 Scottish family, with family members carrying the mutated CHRNB2 codon287 indicated by “m”
In some family members, the seizures have remitted
spontaneously, but the oldest surviving family member
(II-2; fig. 1), at age 81 years, continues to have occasional
seizures while on phenytoin. DNA was only available
from eight members of this family: six affected individ-
uals, one obligate carrier, and his unaffected wife.
The second transmembrane domains (M2) of the
nAChR subunits were screened by direct sequencing.
Products for sequencing and restriction enzyme analysis
were generated using primers A (TTCACACCT-
AGTGGTAGTG) and B (TGGCTGCTGCATGAAGA-
GCA), which amplify a 468-bp segment of theCHRNB2
gene. Products for single-strand conformation analysis
(SSCA) were generated using primers C (CTGCTGC-
TCATCTCCAAGAT) and B, which amplify a 220-bp
segment of the gene. All PCR reactions contained 67
mM Tris-HCl (pH 8.8); 16.5 mM (NH4)2SO4; 6.5 mm
EDTA; 1.5 mM MgCl2; 200 mM each dNTP; 10%
DMSO; 0.17 mg/ml BSA; 10 mM b-mercaptoethanol;
15 mg/ml each primer; 100 U/ml Taq DNA polymerase,
and 10 mg/ml genomic DNA. Reactions for SSCA also
contained 200 mCi/ml [32P-a-]dCTP. Reactions were per-
formed using 10 cycles of 94C for 60 s, 60C for 90 s,
and 72C for 90 s and 25 cycles of 94C for 60 s, 55C
for 90 s, and 72C for 90 s, followed by 10 min at 72C.
PCR-amplified templates were purified for sequencing
using QiaQuick PCR preps (Qiagen). Primers used for
sequencing were the same as those used for PCR. For
each reaction, 25 ng of primer and 100 ng of template
were used. The BigDye sequencing kit (ABI) was used
for sequencing reactions, and the products were ana-
lyzed using an ABI 377 Sequencer and the EditView
program.
Sequencing revealed a GrA transition in the M2 do-
main ofCHRNB2 in the proband and in the other family
members where presence of the mutation has been in-
dicated (fig. 1). The GrA transition created a NlaIII
restriction site. Primers A and B amplify a 468-bp frag-
ment containing four normally present NlaIII sites in
addition to the mutant NlaIII site. Digestion withNlaIII
gives fragments of 318, 78, 54, 9, and 9 bp in the normal
allele and fragments of 273, 78, 54, 45, 9, and 9 bp in
the mutated allele, confirming the presence of the mu-
tation. Bands of 318 bp and 273 bp are easily detected
on 2% agarose gels. The mutation is also detectable by
SSCA in family members with the GrA transition. The
bandshift detected by SSCA could only be associated
with the GrA transition, since no other base changes
were detected in the PCR product. SSCA excluded this
transition in 102 anonymous Australian blood donors.
For SSCA screening of blood donor samples, PCR re-
actions were mixed with an equal volume of formamide
loading buffer (96% formamide, 1 mM EDTA, 0.1%
bromophenol blue, 0.1% xylene cyanol) and were
heated to 95C for 3 min before snap-cooling on ice. 5
ml of each sample was loaded on 10% (49:1) polyacryl-
amide, 5% glycerol and was run on TBE gels. The gels
were run at 700 V for 20 h at room temperature, were
dried, and were exposed to X-ray film.
The c1025GrA mutation replaces a highly conserved
valine with methionine at position 287, using nomen-
clature on the NCBI database (fig. 2), or at position 262,
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Figure 2 DNA sequence of CHRNB2, showing the c1025GrA
transition. The upper chromatogram shows the mutation. The lower
chromatogram shows the control sequence.
Figure 3 Similarities within theM2 domain. Codon 287, located
near the extracellular end of the M2 domain, is indicated by the box.
using the numbering of Rempel et al. (1998). All affected
individuals and the unaffected obligate carrier had the
mutation (fig. 1). There is much homology between
CHRN genes of different species, especially in the four
transmembrane domains. CHRNB2, CHRNB3, and
CHRNB4 all are expressed in brain. The M2 domain
of CHRNB3 has only 59% homology with the other
two, and in vitro studies in the rat show that, when
coexpressed with the a subunits alone, b3 does not as-
semble into a functional receptor. The b3 subunits may
function in ion channels gated by ligands other than
nicotine and acetylcholine (Willoughby et al. 1993). The
M2 domains of CHRNB2 and CHRNB4 are almost
completely conserved, and, in particular, valine287 is
fully conserved (fig. 3). CHRNB1, which is expressed
only in muscle, has leucine at this position. This may
indicate that valine287 is essential for normal ion-chan-
nel function in the brain. The V287M mutation is lo-
cated near the extracellular end of the M2 domain (dark
barrel shown in fig. 4A) that lines the ionic pore. Val-
ine287 faces into the pore of the ion channel in both the
open and the closed state (Devilliers-Thiery et al. 1993),
and, when valine287 is replaced by a bulkiermethionine,
normal ion flow through the channel might be disrupted.
To define the effects of the b2 V287M mutation on
the physiological properties of the a4b2 nAChR, we
introduced the V287M amino acid substitution into the
b2 coding sequence. Mutation V287M was introduced
in the CHRNB2 cDNA (Monteggia et al. 1995), ac-
cording to the PCR-derived strategy described byNelson
and Long (1989). The unique NheI and PmlI restriction
sites were used to ligate the mutated fragment into the
wild-type CHRNB2 cDNA. Mutation V287M was ver-
ified by complete sequencing of the 411-bp mutagenesis
cassette.
Stage V or VI Xenopus laevis oocytes were isolated
and nuclear-injected with 10 nl of 0.2 ng/nl DNA so-
lution according to a standard procedure (Bertrand et
al. 1991). For functional reconstitution of a4b2,
a4b2V287M, and a4(b2b2V287M) receptors, cDNAs
coding for CHRNA4 (a4) (Monteggia et al. 1995),
CHRNB2 (b2), andCHRNB2-V287M (b2V287M) sub-
units were mixed at molecular ratios of 1:1, 1:1, and 2:
1:1, respectively. Oocytes were maintained at 18C for
2–3 d, in standard Barth’s solution containing (in mM):
NaCl 88, KCl 1, NaHCO3 2.4, MgSO4 0.8, Ca(NO3)2
0.3, CaCl2 0.4, HEPES-NaOH 10, pH 7.4, and were
complemented with kanamycin (20 mg/ml), penicillin
(100 mg/ml), and streptomycin (100 mg/ml).
The a4b2 and a4b2V287M cDNA combinations, in-
jected into oocytes in a 1:1 ratio, will be considered first.
Both wild-type and V287M containing receptors (where
all three b2 subunits carried the V287M amino acid
substitution) yielded robust currents (15 mA) when chal-
lenged with saturating acetylcholine (Ach) concentra-
tions. Macroscopic currents were recorded by a two-
electrode voltage clamp, at 18C, using a GENECLAMP
500 amplifier (Axon Instruments). Borosilicate elec-
trodes were filled with 3 M KCl. Oocytes were contin-
uously perfused with OR2 bath solution (Bertrand et al.
1991) containing (in mM): NaCl 82.5, KCl 2.5, CaCl2
2.5, MgCl2 1, atropine sulfate 0.0005, HEPES-NaOH
5, pH 7.4. ACh (Fluka) was diluted in OR2 from a 100-
mM stock solution to the final concentrations used for
experiments. Gravity-driven solutions were applied to
the recording chamber through computer-controlled
electromagnetic valves. For all experiments, holding po-
tential was Vhold p 100 mV.
Distinction between these two types of receptors was
unambiguously observed at low concentrations of ACh.
As shown in the upper panel of fig. 4B, 3 nM ACh was
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Figure 4 A, left panel, Neuronal a4b2 heteropentameric receptor resulting from the assembly of two a4 and three b2 subunits. Right
panel, a4b2 is shown as a pentamer with two potential ACh-binding sites. “b2*” identifies the V287M amino acid substitution. The ACh
receptor can assemble without any mutated b2 subunit (a4b2 wild-type receptor) or with one, two, or three mutated b2* subunits. B, upper
panel, Current traces elicited by consecutive applications of four or five increasing ACh concentrations (horizontal bars). The values above each
bar indicate the concentration of ACh applied to the cell. Lower panel, Differences in ACh affinity are emphasized in a log-log plot. The
logarithm of the absolute value of the current (measured in the upper panel, Log [I]) is plotted as a function of the logarithm of ACh
concentrations (Log [ACh]). I and [ACh] are expressed in nA and nM, respectively. Values are mean  SEM, with (a4b2),np 9 np 17
(a4b2*), and (a4[b2*b2]). Solid lines are the best linear regression throughout data points. C, upper panel,Representativemacroscopicnp 10
currents recorded in oocytes expressing either the wild-type or mutated b2 subunit. Currents evoked by four ACh concentrations (0.1, 0.2, 0.8
and 8 mM) are superimposed. Cells were held at 100 mV and challenged with ACh (10 s) once every 120 s. Bars indicate ACh applications.
Lower panel, ACh activation curves for a4b2, a4b2* and a4(b2*b2). Dose-response curves were normalized to the maximal current amplitude
of each cell. Values are mean  SEM. For each ACh concentration, 3–8 independent measurements were averaged. Values of the curve fits are
given in the text.
already sufficient to activate reliable ionic currents with
the mutated receptor (8124 nA, ). In contrast,np 18
50 nM ACh was required to evoke currents of similar
amplitude in wild-type nAChRs (6522 nA, ).np 9
To characterize these differences, we first recorded cur-
rents evoked by four or five consecutive applications of
increasing ACh concentrations that were non- or slightly
desensitizing. Representative currents are shown in the
upper panel of fig. 4B. A plot of the logarithm of ACh-
evoked current (absolute value) versus the logarithm of
agonist concentrations exhibited the expected linear re-
lationship (fig. 4B, lower panel). Solid lines correspond
to best linear regression fits. The a4b2V287M exhibited
∼1 order of magnitude higher ACh sensitivity than did
wild-type receptors. These data confirmed our initial
qualitative observation that mutated receptors were
more sensitive to ACh.
To further examine ACh sensitivity, we determined,
over a broad range of concentrations, the dose-response
relationship for both control and mutated receptors. Fig-
ure 4C shows superimposed currents evoked by 0.1, 0.2,
0.8, and 8 mM external ACh. Plotting peak current ver-
sus the logarithm of agonist concentration allowed the
determination of the apparent ACh sensitivity (fig. 4C,
lower panel). The recent work of Covernton and Con-
nolly (2000), as well as observations made in our lab
(B. Buisson, personal communication) suggest that a4b2
activation curves are best described by the sum of two
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Table 1
Properties of Wild-Type and b2*-V287M Containing Receptors
Subunit
Combination EC50 (H) EC50 (L) n (H) n (L) % (H) % (L) n
a4b2 3.90  1.30 47.6  18.8 1.2  .2 1.3  .2 26  5 74  5 8
a4b2* .25  .04 2.9  .9 1.6  .1 1.9  .1 77  1.5 23  1.5 7
a4 (b2*b2) .42  .14 5.3  2.3 1.6  .1 1.0  .1 65  3 35  3 7
NOTE.—Sensitivity to ACh was measured in several cells ( ). Values correspond to the best fitsn  5
obtained with equation 1. Values are mean  SEM. Symbols used are as defined for equation (1).
Hill equations (eq. [1], solid lines in fig. 4C, lower panel).
Most of ACh activation curves appeared biphasic with
a high- and low-affinity component (Covernton and
Connolly 2000; B. Buisson, personal communication).
Consequently, ACh dose–response relationships were
best fitted to the sum of two empirical Hill equations:
nHIp I a/(1 EC50H/[ACh]){[ ]max
nL(1 a)/(1 EC50L/[ACh] ) , (1)}
where Imax is the amplitude of the maximal current elic-
ited by ACh application, EC50 is the ACh concentration
for half-maximal current activation, [ACh] is the con-
centration of ACh, and n is the Hill coefficient. Param-
eters related to the high- and low-affinity component are
identified by H and L, respectively. Parameter a is the
relative contribution of the high-affinity component to
the total current response over the range of concentra-
tions. a is expressed as the fraction of the high-affinity
sites.
Corresponding EC50s, Hill slope values, and the rel-
ative contribution of each component, the high-affinity
(H) and low-affinity (L) component, are summarized in
table 1. Within the limits of the model used for the data
fit, the a4b2V287M receptor exhibited both a decrease
in the EC50s and an increase in the relative contribution
of the high-affinity component. Thus, both log-log plot
and dose-response curves accounted for a higher ap-
parent ACh affinity associated with the b2-V287M
mutation.
Determination of the peak-versus-plateau current ra-
tio revealed no major differences between the wild-type
and mutated receptors. This indicates that the V287M
mutation causes no significant alteration of desensiti-
zation properties. Although the slowness of drug appli-
cation on oocytes may prevent detection of very fast
components in the Ach-evoked current, we believe
that our data faithfully reflect the major response
components.
Early studies (Anand et al. 1991; Cooper et al. 1991)
suggest that nAchRs are heteropentamers resulting from
the assembly of two a4 and three b2 subunits. Data
discussed thus far relates to receptors where all three b2
subunits carried the V287M amino acid substitution.
Since patients are heterozygous for the b2 gene, all cells
probably express both the wild-type and mutated sub-
units. Therefore, it is mandatory to coinject wild-type
and mutated b2 subunits. If the two b2 promoters are
equipotent, the first experimental approach would be to
inject equal amounts of wild-type and mutated b2 in the
same oocyte. Within the same batch of oocytes, currents
evoked by saturating ACh concentrations were indistin-
guishable on the basis of their amplitude. In contrast,
an obvious difference was observed for the apparent
ACh affinity. As is shown in table 1, both the high and
low values of EC50 were comparable to receptors con-
taining three V287M b2 subunits. Additionally, the rel-
ative contribution of high- versus low-affinity compo-
nent was similar. Like a4b2V287M, a4(b2b2V287M)
exhibited a higher affinity in the log-log plot (triangles,
fig. 4B).
These findings are consistent with the autosomal dom-
inant mode of transmission of ADNFLE. As schematized
in the right panel of figure 4A, four distinct subunit
compositions are possible when both wild-type and mu-
tated subunits are expressed in a cell. According to this
assembly model, 75% of the receptors contain amutated
b2 subunit. Thus, the dominant effect of the mutation
can be easily accounted for. Interestingly, oocytes ex-
pressing heterozygote or homozygote combination dis-
play very similar properties. This suggests that presence
of a single b2 mutation within a receptor complex may
be sufficient to confer the properties associated with the
V287M substitution.
Thus far, two of the a4 mutations associated with
ADNFLE (Steinlein et al. 1995, 1997) have been ex-
amined for their effect on channel properties. Both mu-
tations introduce an amino acid modification in the M2
domain. Functional characterization of S248F in oocytes
reveals both a significant decrease in currents evoked by
saturating ACh concentrations and a small shift of the
ACh dose-response toward a lower sensitivity. In con-
trast, mutation 776insGCT, which introduces an addi-
tional leucine residue into the M2 domain (259insL),
does not affect the amplitude of ionic currents but causes
an apparent increase of the ACh affinity of ∼10-fold.
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Consequently, although affecting different subunits, mu-
tations a4 259insL and b2 V287M result in similar al-
terations of the functional properties of the receptor.
Interestingly, although b2 V287M causes no significant
alteration of desensitization properties, the major effect
of b2 V287L is retardation of channel desensitization
(De Fusco et al. 2000).
CHRNB2 is a new gene for idiopathic epilepsy and
the second nAChR subunit implicated in ADNFLE. This
confirms genetic heterogeneity for ADNFLE established
by linkage analysis (Oldani et al. 1998; Phillips et al.
1998). Although only two mutations have so far been
detected within the b2 subunit, the fact that both affect
different amino acid substitutions at the same site sug-
gests the possibility of site-specific mutation similar to
that now established for the a4 subunit (Phillips et al.
2000). Questions yet to be answered include how all the
various mutations identified so far in a4 and b2 subunits
can lead to similar epileptic seizures and which other
neurotransmitter systems might be involved for NFLE
cases with normal nAChR subunits.
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